305 related articles for article (PubMed ID: 11406532)
21. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
22. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression.
Dubey P; Wu H; Reiter RE; Witte ON
Cancer Res; 2001 Apr; 61(8):3256-61. PubMed ID: 11309275
[TBL] [Abstract][Full Text] [Related]
23. Human bladder cancer associated antigens: evaluation of antigenicity in TCC tissues of different grades and in normal urothelium.
Ben-Aïssa H; Paulie S; Gustafsson B; Håkansson L; Lagerkvist M; Gustafson H; Ahlstrand C; Perlmann P
Anticancer Res; 1988; 8(3):443-9. PubMed ID: 3389746
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma.
Croft PR; Lathrop SL; Feddersen RM; Joste NE
Arch Pathol Lab Med; 2005 Feb; 129(2):194-9. PubMed ID: 15679420
[TBL] [Abstract][Full Text] [Related]
25. Quantum-dot-based technology for sensitive and stable detection of prostate stem cell antigen expression in human transitional cell carcinoma.
Cheng F; Yu W; Zhang X; Ruan Y
Int J Biol Markers; 2009; 24(4):271-6. PubMed ID: 20082273
[TBL] [Abstract][Full Text] [Related]
26. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas.
Izadifar V; de Boer WI; Muscatelli-Groux B; Maillé P; van der Kwast TH; Chopin DK
Hum Pathol; 1999 Apr; 30(4):372-7. PubMed ID: 10208456
[TBL] [Abstract][Full Text] [Related]
27. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers.
Yu Y; Yang JL; Markovic B; Jackson P; Yardley G; Barrett J; Russell PJ
Clin Cancer Res; 1997 Jul; 3(7):1045-9. PubMed ID: 9815782
[TBL] [Abstract][Full Text] [Related]
28. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
[TBL] [Abstract][Full Text] [Related]
29. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
30. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
Kohaar I; Porter-Gill P; Lenz P; Fu YP; Mumy A; Tang W; Apolo AB; Rothman N; Baris D; Schned AR; Ylaya K; Schwenn M; Johnson A; Jones M; Kida M; Silverman DT; Hewitt SM; Moore LE; Prokunina-Olsson L
J Natl Cancer Inst; 2013 Jan; 105(1):69-73. PubMed ID: 23266392
[TBL] [Abstract][Full Text] [Related]
31. Identification of genes correlated with early-stage bladder cancer progression.
Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
[TBL] [Abstract][Full Text] [Related]
32. Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis.
Ross S; Spencer SD; Lasky LA; Koeppen H
Am J Pathol; 2001 Mar; 158(3):809-16. PubMed ID: 11238029
[TBL] [Abstract][Full Text] [Related]
33. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.
Chopin D; Barei-Moniri R; Maillé P; Le Frère-Belda MA; Muscatelli-Groux B; Merendino N; Lecerf L; Stoppacciaro A; Velotti F
Am J Pathol; 2003 Apr; 162(4):1139-49. PubMed ID: 12651606
[TBL] [Abstract][Full Text] [Related]
34. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
[TBL] [Abstract][Full Text] [Related]
35. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.
Muraoka K; Nabeshima K; Murayama T; Biswas C; Koono M
Int J Cancer; 1993 Aug; 55(1):19-26. PubMed ID: 8344748
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
37. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
[TBL] [Abstract][Full Text] [Related]
38. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
39. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
40. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
